Komodo,
Congress,
Partnership,
WGS,
Research,
Life,
Disease,
GeneDx,
Patient,
Diagnosis,
Standard of care,
Clinical trial,
Drug discovery,
Medicine,
Pharmaceutical industry STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry.
Key Points:
- STAMFORD, Conn., April 23, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced a strategic partnership with Komodo Health, a premier healthcare technology company for the pharmaceutical industry.
- The new partnership will increase access to GeneDx's extensive de-identified rare disease data set, now available through Komodo Health’s MapEnhance offering, including data from more than 500,000 exomes, enabling biopharma companies to access genetic insights that can help inform drug pipelines and accelerate clinical trial enrollment.
- “The partnership between GeneDx and Komodo Health represents a milestone in advancing the understanding of rare disease and its associated drug development”, said Melanie Duquette, Chief Growth Officer, GeneDx.
- GeneDx is continuing to showcase its value to biopharma companies through its participation in the World Orphan Drug Congress meeting in Boston, April 23-25th.
STAMFORD, Conn., April 04, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2024 after the market closes on Monday, April 29, 2024.
Key Points:
- STAMFORD, Conn., April 04, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2024 after the market closes on Monday, April 29, 2024.
- Management will host a conference call that day to discuss first quarter 2024 financial and operating results at 4:30 p.m. Eastern Time.
- Investors interested in listening to the conference call are required to register online.
- A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/ .
Diagnosis,
WGS,
P130,
HZ,
P180,
Conference,
Genetic testing,
SLC16A2,
CMA,
Patient,
Medical genetics,
Research,
A-DNA,
Impact,
American College,
VUS,
Fire,
ACMG,
Syndrome,
GeneDx,
Analysis,
Medical device STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.
Key Points:
- STAMFORD, Conn., March 14, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.
- These findings represent improved data quality from pipeline and platform improvements.
- Through an industry-sponsored session, GeneDx will explore the gap between the availability of the medical genetics workforce and the genetic testing needs of pediatric patients.
- "We are motivated to continue to push the boundaries of genomics to transform the future of healthcare," said Paul Kruszka, Chief Medical Officer at GeneDx.
STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Cowen Healthcare Conference from March 4-6 in Boston, MA.
Key Points:
- STAMFORD, Conn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Cowen Healthcare Conference from March 4-6 in Boston, MA.
- Management will participate in a fireside chat on Wednesday, March 6, 2024, at 10:30 a.m.
- ET.
- A live and archived webcast of the presentation will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.
Montefiore,
VUS,
Genetics in Medicine,
Total,
Legacy,
Abraxis BioScience,
Partnership,
Exome,
DSM-IV codes,
WGS,
Commercial,
GAAP,
American College,
ACMG,
Genome,
Genetic testing,
Medicaid,
Genetics,
Google Health,
Medical genetics,
Publication,
NICU,
Bank Key Points:
- ET
STAMFORD, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the fourth quarter and full year of 2023.
- Exome and genome represented 27% of all test results, up from 16% in the fourth quarter of 2022 and up from 23% in the third quarter of 2023.
- Adjusted gross margin from continuing operations expanded to 56%, up from 41% in the fourth quarter of 2022 and up from 48% in the third quarter of 2023.
- Excluding one-time items, representative continuing operations cash burn was $23.9 million in the fourth quarter of 2023.
STAMFORD, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter of 2023 after the market closes on Tuesday, February 20, 2024.
Key Points:
- STAMFORD, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financial results for the fourth quarter of 2023 after the market closes on Tuesday, February 20, 2024.
- Management will host a conference call that day to discuss 2023 financial and operating results and share full year 2024 guidance at 4:30 p.m. Eastern Time.
- Investors interested in listening to the conference call are required to register online.
- A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/ .
The RSUs were granted under GeneDx’s 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
Key Points:
- The RSUs were granted under GeneDx’s 2023 Equity Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
- The inducement RSUs will vest in equal annual installments over the four-year period following the grant date, subject to the employee’s continued service with the Company on each applicable vesting date.
- Each RSU represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement.
- Typically, upon full vesting, shares are sold to cover tax withholding obligations in connection with the vesting and settlement of RSUs and funded by a "sell to cover" transaction.
Annual report,
Risk,
Exome,
Growth,
Eye,
Bank statement,
Legacy,
Genome,
Intelligence,
WGS,
GeneDx,
Video game STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported preliminary financial results for the fourth quarter and full year of 2023.
Key Points:
- STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported preliminary financial results for the fourth quarter and full year of 2023.
- The preliminary, unaudited results presented in this press release for the year ended December 31, 2023, are based on current expectations and are subject to adjustment, as the company completes the preparation of its 2023 year-end consolidated financial statements and its 2023 year-end audit.
- GeneDx will release financial results for the fourth quarter and full year of 2023 after the market closes on Tuesday, February 20, 2024.
- On the same day, Katherine Stueland, President and Chief Executive Officer of GeneDx, and Kevin Feeley, Chief Financial Officer of GeneDx, will host a conference call to discuss financial and operating results at 4:30 p.m. Eastern Time.
Patient,
Conference,
Hospital,
Seizure,
Genetic counseling,
Whole genome sequencing,
Epilepsy,
AES,
American Epilepsy Society,
Diet,
National Society,
DSM-IV codes,
MD,
Doctor of Philosophy,
Research,
Health,
NSGC,
Parent,
Insurance,
Test management,
Genetic testing,
FACMG,
Medicaid,
Diagnosis,
Clinical,
WGS,
Michelle,
GeneDx The gap in diagnosis between exome sequencing and the multi-gene epilepsy panels can be largely attributed to the fact that more than half (57%) of seizure-related genes are not included on many commercially available epilepsy panels.
Key Points:
- The gap in diagnosis between exome sequencing and the multi-gene epilepsy panels can be largely attributed to the fact that more than half (57%) of seizure-related genes are not included on many commercially available epilepsy panels.
- Of those patients with a positive genetic diagnosis from exome sequencing, 11% had a variant in a treatment related gene.
- GeneDx will also present data at the conference that shows insurance may offer better coverage for exome sequencing than multi-gene panels for patients with epilepsy.
- At the conference, GeneDx will also be hosting an industry sponsored symposium discussing the ways in which exome sequencing can help epilepsy patients find answers sooner.
STAMFORD, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Evercore ISI HealthCONx Conference this week in Miami, FL.
Key Points:
- STAMFORD, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Evercore ISI HealthCONx Conference this week in Miami, FL.
- Katherine Stueland, President and Chief Executive Officer, will participate in a fireside chat on Thursday, November 30, 2023, at 10:50 a.m.
- ET.
- A live and archived webcast of the presentation will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.
